NCT02336555View on ClinicalTrials.gov

The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 12, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Postherpetic Neuralgia
Interventions
DRUG

MK-8291

MK-8291 oral tablets

DRUG

Placebo

Placebo oral tablets

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02336555 - The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012) | Biotech Hunter | Biotech Hunter